 CINCINNATI, Feb. 16, 2021 GLOBE NEWSWIRE -- Meridian Bioscience, Inc. NASDAQ: VIVO, a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization EUA with the U.S. Food and Drug Administration FDA for the SARS-CoV-2 molecular diagnostic test on its Revogene platform. 